ArticleCureus2024
Multimodal Therapy in Multidrug-Resistant Prostatitis: A Case Report and Review of the Literature.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic bacterial prostatitis is generally difficult to treat. It may involve multiple courses of antibiotics and may be difficult to eradicate with high rates of recurrence. We present the case of a 33-year-old male patient with a previous history of renal tract calculi, stent insertions, and perinephric abscess with percutaneous drainage, which then led to a right nephrectomy. He eventually developed recurrent urinary tract infections with the prostate as the source. This patient had at least two prior, prolonged courses of intravenous antibiotics, one consisted of two weeks and the other of six weeks of intravenous meropenem at different times. His last episode of prostatitis was managed with intraprostatic injections of lidocaine and a mixture of amikacin and meropenem, given at once-a-week intervals for four weeks along with simultaneous thrice-daily meropenem during this period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.